\-\ Texto\\:\\ \ \(0\)\
\-\ rle\\ \\‚\\Ä\\ì\\ tenderness\\ to\\ palpation\\ over\\ posterior\\ right\\ pelvis\\ with\\ difficulty\\ moving\\ right\\ hip\\ due\\ to\\ pain\\.\\ full\\ active\\ range\\ of\\ motion\\ of\\ his\\ right\\ knee\\ and\\ right\\ foot\\.\\ 5\\/5\\ motor\\ strength\\ of\\ his\\ quads\\,\\ hamstrings\\,\\ anterior\\ tibialis\\,\\ and\\ extensor\\ hallucis\\ longus\\.\\ \\ lle\\ \\‚\\Ä\\ì\\ no\\ tenderness\\ to\\ palpation\\,\\ no\\ pain\\ with\\ arom\\ of\\ hip\\,\\ knee\\,\\ ankle\\,\\ or\\ foot\\.\\ no\\ obvious\\ deformities\\,\\ sensation\\ intact\\ throughout\\ with\\ 5\\/5\\ motor\\ strength\\ in\\ quads\\,\\ hamstrings\\,\\ extensor\\ hallucis\\ longus\\.\\ and\\ anterior\\ tibialis\\.\\ \ \(0\)\
\-\ wbc\\:\\ 10\\.6\ \(0\)\
\-\ crp\\:\\ 11\\.1\\ \ \(0\)\
\-\ esr\\:\\ 42\ \(0\)\
\-\ surgical\\ resection\\,\\ chemotherapy\\,\\ radiotherapy\ \(0\)\
\-\ mri\\ lumbar\\ spine\\:\\ heterogeneous\\ mass\\ in\\ the\\ right\\ iliac\\ wing\\ with\\ extension\\ into\\ the\\ soft\\ tissues\\ laterally\ \(0\)\
\-\ ewing\\ sarcoma\ \(0\)\
\-\ 1\\.\\	ewings\\ sarcoma\ \(0\)\
\-\ 2\\.\\	chondrosacroma\ \(0\)\
\-\ 3\\.\\	pnet\ \(0\)\
\-\ patient\\ is\\ a\\ 19\\ year\\ old\\ male\\ who\\ has\\ a\\ history\\ of\\ 4\\ month\\ history\\ of\\ chronic\\ pain\\ in\\ the\\ right\\ side\\ of\\ his\\ low\\ back\\.\\ his\\ pain\\ became\\ progressively\\ severe\\ and\\ an\\ mri\\ was\\ obtained\\ which\\ showed\\ an\\ invasive\\ large\\ mass\\ in\\ the\\ right\\ iliac\\ bone\\ with\\ extension\\ into\\ the\\ adjacent\\ soft\\ tissue\\ and\\ right\\ sacroiliac\\ joint\\.\\ there\\ was\\ bone\\ marrow\\ edema\\.\\ initial\\ evaluation\\ showed\\ a\\ small\\ blue\\ round\\ tumor\\.\ \(0\)\
\-\ case\\ contributors\\:\\ matthew\\ gayed\\,\\ dawn\\ light\ \(0\)\
\-\ discussion\\ \\(include\\ references\\)\\:\\ \ \(0\)\
\-\ ewing\\ sarcoma\\ is\\ a\\ neuroectodermal\\ malignant\\ small\\ round\\ blue\\ cell\\ tumor\\.\\ although\\ overall\\ rare\\,\\ ewing\\ sarcoma\\ is\\ the\\ second\\ most\\ common\\ primary\\ bone\\ malignancy\\ in\\ children\\.\\ the\\ typically\\ sites\\ in\\ which\\ the\\ cancer\\ cells\\ appear\\ are\\ the\\ femur\\,\\ the\\ pelvis\\,\\ the\\ humerus\\,\\ and\\ the\\ ribs\\.\\ it\\ most\\ commonly\\ occurs\\ in\\ adolescent\\ males\\ less\\ than\\ 15\\ years\\ of\\ age\\.\\ most\\ cases\\ of\\ ewing\\ sarcoma\\ are\\ due\\ to\\ the\\ translocation\\ between\\ chromosomes\\ 11\\ and\\ 22\\ \\(1\\)\\.\\ the\\ clinical\\ presentation\\ includes\\ localized\\ pain\\ \\(worse\\ at\\ night\\ and\\ intensified\\ by\\ exercise\\)\\ and\\ swelling\\ for\\ weeks\\ or\\ months\\ with\\ erythema\\ and\\ warmth\\ of\\ the\\ local\\ area\\ \\(2\\)\\.\\ trauma\\ may\\ be\\ the\\ initiating\\ incident\\ that\\ brings\\ attention\\ to\\ the\\ lesion\\.\\ up\\ to\\ 20\\%\\ of\\ patients\\ may\\ also\\ have\\ systemic\\ symptoms\\,\\ such\\ as\\ fever\\,\\ fatigue\\,\\ weight\\ loss\\,\\ or\\ anemia\\ \\(3\\)\\.\\ nearly\\ all\\ patients\\ with\\ this\\ sarcoma\\ are\\ presumed\\ to\\ have\\ a\\ subclinical\\ metastatic\\ disease\\ because\\ 80\\ to\\ 90\\ percent\\ of\\ patients\\ relapse\\ after\\ local\\ therapy\\ alone\\ \\(4\\)\\.\\ of\\ all\\ the\\ tumor\\ sites\\,\\ patients\\ with\\ pelvic\\ tumors\\ have\\ the\\ highest\\ percentage\\ \\(25\\%\\)\\ of\\ concurrent\\ metastatic\\ disease\\ \\(5\\)\\.\\ the\\ spine\\ and\\ lungs\\ are\\ the\\ most\\ frequently\\ involved\\ site\\ of\\ metastasis\\ and\\ lung\\ metastases\\ are\\ the\\ leading\\ cause\\ of\\ death\\ in\\ patients\\ with\\ ewing\\ sarcoma\\.\\ \\ this\\ sarcoma\\ may\\ be\\ confused\\ with\\ osteomyelitis\\ due\\ to\\ the\\ increased\\ esr\\,\\ fever\\,\\ leukocytosis\\,\\ and\\ anemia\\.\\ it\\ may\\ also\\ be\\ confused\\ with\\ a\\ primary\\ lymphoma\\ of\\ the\\ bone\\ but\\ this\\ can\\ be\\ differentiated\\ as\\ lymphoma\\ of\\ bone\\ occurs\\ in\\ older\\ age\\ groups\\ and\\ is\\ associated\\ with\\ less\\ bone\\ destruction\\ than\\ es\\.\\ on\\ imaging\\,\\ ewing\\ sarcoma\\ is\\ characterized\\ radiographically\\ with\\ its\\ lamellated\\ appearance\\ or\\ \\‚\\Ä\\úonion\\ skin\\‚\\Ä\\ù\\ periosteal\\ reaction\\.\\ the\\ bony\\ lesion\\ is\\ usually\\ lytic\\,\\ central\\,\\ and\\ accompanied\\ by\\ endosteal\\ scalloping\\.\\ the\\ \\‚\\Ä\\úonion\\-skin\\‚\\Ä\\ù\\ appearance\\ is\\ often\\ associated\\ with\\ a\\ \\‚\\Ä\\úmoth\\-eaten\\‚\\Ä\\ù\\ or\\ mottled\\ appearance\\ to\\ the\\ underlying\\ bone\\ and\\ a\\ soft\\ tissue\\ mass\\.\\ the\\ treatment\\ includes\\ surgery\\,\\ radiation\\,\\ and\\ multi\\-drug\\ chemotherapy\\.\\ \ \(0\)\
\-\ references\\ below\ \(1\)\
\-\ references\\:\\ \ \(0\)\
\-\ \\(1\\)\\ medicine\\,\\ s\\ cecil\\.\\ goldman\\ \\(24th\\ ed\\.\\)\\.\\ philadelphia\\:\\ elsevier\\ saunders\\.\\ p\\.\\ 1326\\.\ \(0\)\
\-\ \\(2\\)\\ widhe\\ b\\,\\ widhe\\ t\\.\\ initial\\ symptoms\\ and\\ clinical\\ features\\ in\\ osteosarcoma\\ and\\ ewing\\ sarcoma\\.\\ j\\ bone\\ joint\\ surg\\ am\\ 2000\\;\\ 82\\:667\\.\ \(0\)\
\-\ \\(3\\)\\ rud\\ np\\,\\ reiman\\ hm\\,\\ pritchard\\ dj\\,\\ et\\ al\\.\\ extraosseous\\ ewing\\'s\\ sarcoma\\.\\ a\\ study\\ of\\ 42\\ cases\\.\\ cancer\\ 1989\\;\\ 64\\:1548\\.\ \(0\)\
\-\ \\(4\\)\\ rud\\ np\\,\\ reiman\\ hm\\,\\ pritchard\\ dj\\,\\ et\\ al\\.\\ extraosseous\\ ewing\\'s\\ sarcoma\\.\\ a\\ study\\ of\\ 42\\ cases\\.\\ cancer\\ 1989\\;\\ 64\\:1548\\.\ \(0\)\
\-\ \\(5\\)\\ cotterill\\ sj\\,\\ ahrens\\ s\\,\\ paulussen\\ m\\,\\ et\\ al\\.\\ prognostic\\ factors\\ in\\ ewing\\'s\\ tumor\\ of\\ bone\\:\\ analysis\\ of\\ 975\\ patients\\ from\\ the\\ european\\ intergroup\\ cooperative\\ ewing\\'s\\ sarcoma\\ study\\ group\\.\\ j\\ clin\\ oncol\\ 2000\\;\\ 18\\:3108\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ewing\\:\\ 0\\.07602641260318926\ \(0\)\
\-\ sarcoma\\:\\ 0\\.06534145401362372\ \(0\)\
\-\ bone\\:\\ 0\\.025245590664648387\ \(0\)\
\-\ quads\\:\\ 0\\.023290669548128133\ \(0\)\
\-\ widhe\\:\\ 0\\.023290669548128133\ \(0\)\
\-\ reiman\\:\\ 0\\.023290669548128133\ \(0\)\
\-\ pritchard\\:\\ 0\\.023290669548128133\ \(0\)\
\-\ 64\\:1548\\:\\ 0\\.023290669548128133\ \(0\)\
\-\ hm\\:\\ 0\\.021459369203187723\ \(0\)\
\-\ rud\\:\\ 0\\.020388127173839865\ \(0\)\
\-\ np\\:\\ 0\\.020388127173839865\ \(0\)\
\-\ hamstrings\\:\\ 0\\.019628068858247312\ \(0\)\
\-\ extraosseous\\:\\ 0\\.019628068858247312\ \(0\)\
\-\ dj\\:\\ 0\\.019038521827034076\ \(0\)\
\-\ patients\\:\\ 0\\.017528992861553704\ \(0\)\
\-\ tibialis\\:\\ 0\\.017207221482093665\ \(0\)\
\-\ 42\\:\\ 0\\.017147485023385832\ \(0\)\
\-\ 1989\\:\\ 0\\.016955411231619887\ \(0\)\
\-\ hallucis\\:\\ 0\\.015375921137153255\ \(0\)\
\-\ longus\\:\\ 0\\.015247017136705614\ \(0\)\
\-\ blue\\:\\ 0\\.014894226139018632\ \(0\)\
\-\ \\,\\:\\ 0\\.014661971844397334\ \(0\)\
\-\ al\\:\\ 0\\.014356254582865076\ \(0\)\
\-\ references\\:\\ 0\\.014079900535250777\ \(0\)\
\-\ et\\:\\ 0\\.013860231559269279\ \(0\)\
\-\ extensor\\:\\ 0\\.013611510641576887\ \(0\)\
\-\ \\:\\:\\ 0\\.013437877600945818\ \(0\)\
\-\ \\(\\:\\ 0\\.013359397843347488\ \(0\)\
\-\ confused\\:\\ 0\\.01335354903110419\ \(0\)\
\-\ \\)\\:\\ 0\\.013196205666560466\ \(0\)\
\-\ 2000\\:\\ 0\\.013062925794078223\ \(0\)\
\-\ his\\:\\ 0\\.01301394466392038\ \(0\)\
\-\ \\‚\\Ä\\ú\\:\\ 0\\.012647956081027053\ \(0\)\
\-\ \\‚\\Ä\\ù\\:\\ 0\\.012577059523230056\ \(0\)\
\-\ 5\\/5\\:\\ 0\\.012562946931096643\ \(0\)\
\-\ sites\\:\\ 0\\.01230286747848567\ \(0\)\
\-\ chondrosacroma\\:\\ 0\\.011645334774064067\ \(0\)\
\-\ gayed\\:\\ 0\\.011645334774064067\ \(0\)\
\-\ dawn\\:\\ 0\\.011645334774064067\ \(0\)\
\-\ intensified\\:\\ 0\\.011645334774064067\ \(0\)\
\-\ multi\\-drug\\:\\ 0\\.011645334774064067\ \(0\)\
\-\ 24th\\:\\ 0\\.011645334774064067\ \(0\)\
\-\ 1326\\:\\ 0\\.011645334774064067\ \(0\)\
\-\ 82\\:667\\:\\ 0\\.011645334774064067\ \(0\)\
\-\ cotterill\\:\\ 0\\.011645334774064067\ \(0\)\
\-\ paulussen\\:\\ 0\\.011645334774064067\ \(0\)\
\-\ 975\\:\\ 0\\.011645334774064067\ \(0\)\
\-\ intergroup\\:\\ 0\\.011645334774064067\ \(0\)\
\-\ 18\\:3108\\:\\ 0\\.011645334774064067\ \(0\)\
\-\ esr\\:\\ 0\\.011431656682257223\ \(0\)\
\-\ cases\\:\\ 0\\.011281945299793128\ \(0\)\
\-\ iliac\\:\\ 0\\.01125929070638298\ \(0\)\
\-\ anemia\\:\\ 0\\.011231625449137812\ \(0\)\
\-\ study\\:\\ 0\\.011142528494821502\ \(0\)\
\-\ cancer\\:\\ 0\\.011132755340943587\ \(0\)\
\-\ onion\\-skin\\:\\ 0\\.010729684601593861\ \(0\)\
\-\ goldman\\:\\ 0\\.010729684601593861\ \(0\)\
\-\ ahrens\\:\\ 0\\.010729684601593861\ \(0\)\
\-\ \\;\\:\\ 0\\.010702357666856505\ \(0\)\
\-\ tumor\\:\\ 0\\.010526987062672714\ \(0\)\
\-\ most\\:\\ 0\\.01042449216236764\ \(0\)\
\-\ local\\:\\ 0\\.010370328390342786\ \(0\)\
\-\ j\\:\\ 0\\.010197335181942503\ \(0\)\
\-\ arom\\:\\ 0\\.010194063586919933\ \(0\)\
\-\ onion\\:\\ 0\\.010194063586919933\ \(0\)\
\-\ cecil\\:\\ 0\\.010194063586919933\ \(0\)\
\-\ \\‚\\Ä\\ì\\:\\ 0\\.010160383419789955\ \(0\)\
\-\ strength\\:\\ 0\\.010017537392655804\ \(0\)\
\-\ \\'s\\:\\ 0\\.009955332197448059\ \(0\)\
\-\ may\\:\\ 0\\.009903980813200127\ \(0\)\
\-\ matthew\\:\\ 0\\.009814034429123656\ \(0\)\
\-\ translocation\\:\\ 0\\.009814034429123656\ \(0\)\
\-\ round\\:\\ 0\\.009753116101884384\ \(0\)\
\-\ appearance\\:\\ 0\\.009685230819291842\ \(0\)\
\-\ right\\:\\ 0\\.009528472487296345\ \(0\)\
\-\ chromosomes\\:\\ 0\\.009519260913517038\ \(0\)\
\-\ initiating\\:\\ 0\\.009519260913517038\ \(0\)\
\-\ es\\:\\ 0\\.009519260913517038\ \(0\)\
\-\ lamellated\\:\\ 0\\.009519260913517038\ \(0\)\
\-\ moth\\-eaten\\:\\ 0\\.009519260913517038\ \(0\)\
\-\ 4\\:\\ 0\\.009435819967684458\ \(0\)\
\-\ motor\\:\\ 0\\.00942799036144257\ \(0\)\
\-\ foot\\:\\ 0\\.009332403422003989\ \(0\)\
\-\ 11\\.1\\:\\ 0\\.009278413414449727\ \(0\)\
\-\ subclinical\\:\\ 0\\.009278413414449727\ \(0\)\
\-\ occurs\\:\\ 0\\.009266184218138159\ \(0\)\
\-\ includes\\:\\ 0\\.009101401310010134\ \(0\)\
\-\ european\\:\\ 0\\.009074779755496943\ \(0\)\
\-\ due\\:\\ 0\\.009036765467448506\ \(0\)\
\-\ hip\\:\\ 0\\.008993057786291832\ \(0\)\
\-\ brings\\:\\ 0\\.00889838425665345\ \(0\)\
\-\ sj\\:\\ 0\\.00889838425665345\ \(0\)\
\-\ rle\\:\\ 0\\.008742792399775797\ \(0\)\
\-\ relapse\\:\\ 0\\.008742792399775797\ \(0\)\
\-\ oncol\\:\\ 0\\.008742792399775797\ \(0\)\
\-\ cooperative\\:\\ 0\\.008603610741046833\ \(0\)\
\-\ lle\\:\\ 0\\.008477705615809943\ \(0\)\
\-\ adolescent\\:\\ 0\\.008477705615809943\ \(0\)\
\-\ highest\\:\\ 0\\.008362763241979522\ \(0\)\
\-\ 10\\.6\\:\\ 0\\.008257026507932577\ \(0\)\
\-\ elsevier\\:\\ 0\\.008257026507932577\ \(0\)\
\-\ soft\\:\\ 0\\.008246737505918957\ \(0\)\
\-\ pelvis\\:\\ 0\\.008203676107243405\ \(0\)\
\-\ knee\\:\\ 0\\.008186237047715393\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.00809232704132329\ \(0\)\
\-\ extension\\:\\ 0\\.008058988959528807\ \(0\)\
\-\ ewings\\:\\ 0\\.007982734084183245\ \(0\)\
\-\ neuroectodermal\\:\\ 0\\.007982734084183245\ \(0\)\
\-\ percentage\\:\\ 0\\.007827142227305593\ \(0\)\
\-\ concurrent\\:\\ 0\\.007827142227305593\ \(0\)\
\-\ mottled\\:\\ 0\\.007827142227305593\ \(0\)\
\-\ t\\.\\:\\ 0\\.007827142227305593\ \(0\)\
\-\ are\\:\\ 0\\.00769401501010305\ \(0\)\
\-\ incident\\:\\ 0\\.007687960568576627\ \(0\)\
\-\ less\\:\\ 0\\.007645812428857814\ \(0\)\
\-\ fever\\:\\ 0\\.007638738775566621\ \(0\)\
\-\ sacroiliac\\:\\ 0\\.007562055443339739\ \(0\)\
\-\ prognostic\\:\\ 0\\.007562055443339739\ \(0\)\
\-\ palpation\\:\\ 0\\.007534845654816518\ \(0\)\
\-\ initial\\:\\ 0\\.007481062465731329\ \(0\)\
\-\ spine\\:\\ 0\\.007434883873197748\ \(0\)\
\-\ showed\\:\\ 0\\.007402386441013729\ \(0\)\
\-\ have\\:\\ 0\\.007333308104485172\ \(0\)\
\-\ joint\\:\\ 0\\.007301001994827163\ \(0\)\
\-\ warmth\\:\\ 0\\.007291521212631664\ \(0\)\
\-\ groups\\:\\ 0\\.007243479410556531\ \(0\)\
\-\ endosteal\\:\\ 0\\.007243479410556531\ \(0\)\
\-\ wing\\:\\ 0\\.00710902406800707\ \(0\)\
\-\ saunders\\:\\ 0\\.00706708391171304\ \(0\)\
\-\ be\\:\\ 0\\.006963047415291568\ \(0\)\
\-\ attention\\:\\ 0\\.006948705894949913\ \(0\)\
\-\ leukocytosis\\:\\ 0\\.006948705894949913\ \(0\)\
\-\ accompanied\\:\\ 0\\.006948705894949913\ \(0\)\
\-\ scalloping\\:\\ 0\\.006948705894949913\ \(0\)\
\-\ clinical\\:\\ 0\\.006946657331746379\ \(0\)\
\-\ moving\\:\\ 0\\.006911492054835388\ \(0\)\
\-\ crp\\:\\ 0\\.006911492054835388\ \(0\)\
\-\ pain\\:\\ 0\\.0068930526256983805\ \(0\)\
\-\ radiotherapy\\:\\ 0\\.006875297901350427\ \(0\)\
\-\ age\\:\\ 0\\.006871625694965143\ \(0\)\
\-\ tenderness\\:\\ 0\\.006866346956094144\ \(0\)\
\-\ pnet\\:\\ 0\\.006840069041268312\ \(0\)\
\-\ surg\\:\\ 0\\.006739691357017424\ \(0\)\
\-\ primary\\:\\ 0\\.006687937286382289\ \(0\)\
\-\ clin\\:\\ 0\\.006646405270869534\ \(0\)\
\-\ or\\:\\ 0\\.006615077602138095\ \(0\)\
\-\ 5\\:\\ 0\\.006605443652428437\ \(0\)\
\-\ males\\:\\ 0\\.006504224736929817\ \(0\)\
\-\ s\\:\\ 0\\.006474947601359543\ \(0\)\
\-\ lymphoma\\:\\ 0\\.006452308148981468\ \(0\)\
\-\ presumed\\:\\ 0\\.006400563421947658\ \(0\)\
\-\ all\\:\\ 0\\.006385531015670518\ \(0\)\
\-\ deformities\\:\\ 0\\.006375871040161458\ \(0\)\
\-\ laterally\\:\\ 0\\.006327829238086326\ \(0\)\
\-\ philadelphia\\:\\ 0\\.006327829238086326\ \(0\)\
\-\ radiographically\\:\\ 0\\.006236689381432494\ \(0\)\
\-\ nearly\\:\\ 0\\.006214854108049124\ \(0\)\
\-\ percent\\:\\ 0\\.006151433739242835\ \(0\)\
\-\ in\\:\\ 0\\.006123341521192608\ \(0\)\
\-\ alone\\:\\ 0\\.006110784256195604\ \(0\)\
\-\ became\\:\\ 0\\.00609091916060176\ \(0\)\
\-\ ribs\\:\\ 0\\.00609091916060176\ \(0\)\
\-\ death\\:\\ 0\\.00609091916060176\ \(0\)\
\-\ progressively\\:\\ 0\\.006071348373567227\ \(0\)\
\-\ contributors\\:\\ 0\\.006033055722479708\ \(0\)\
\-\ fatigue\\:\\ 0\\.006033055722479708\ \(0\)\
\-\ differentiated\\:\\ 0\\.006033055722479708\ \(0\)\
\-\ than\\:\\ 0\\.005915584821448544\ \(0\)\
\-\ osteosarcoma\\:\\ 0\\.005873276844781343\ \(0\)\
\-\ group\\:\\ 0\\.005873276844781343\ \(0\)\
\-\ m\\:\\ 0\\.005824041184547219\ \(0\)\
\-\ anterior\\:\\ 0\\.005814512083917404\ \(0\)\
\-\ humerus\\:\\ 0\\.005808028819246896\ \(0\)\
\-\ am\\:\\ 0\\.005808028819246896\ \(0\)\
\-\ exercise\\:\\ 0\\.005792208223412396\ \(0\)\
\-\ p\\:\\ 0\\.005792208223412396\ \(0\)\
\-\ analysis\\:\\ 0\\.005745852450874392\ \(0\)\
\-\ obvious\\:\\ 0\\.005701068366758565\ \(0\)\
\-\ older\\:\\ 0\\.005686471489365454\ \(0\)\
\-\ metastatic\\:\\ 0\\.0056832480940979925\ \(0\)\
\-\ invasive\\:\\ 0\\.005672034143880393\ \(0\)\
\-\ to\\:\\ 0\\.005641586637291761\ \(0\)\
\-\ symptoms\\:\\ 0\\.005626571933680684\ \(0\)\
\-\ overall\\:\\ 0\\.005615812724568906\ \(0\)\
\-\ characterized\\:\\ 0\\.005615812724568906\ \(0\)\
\-\ destruction\\:\\ 0\\.005575163241521676\ \(0\)\
\-\ erythema\\:\\ 0\\.005548742281539285\ \(0\)\
\-\ localized\\:\\ 0\\.00549743470780578\ \(0\)\
\-\ night\\:\\ 0\\.005484913249477453\ \(0\)\
\-\ systemic\\:\\ 0\\.005400436730850934\ \(0\)\
\-\ leading\\:\\ 0\\.005400436730850934\ \(0\)\
\-\ ankle\\:\\ 0\\.005377260628273776\ \(0\)\
\-\ into\\:\\ 0\\.005372064380342686\ \(0\)\
\-\ 1\\:\\ 0\\.005372064380342686\ \(0\)\
\-\ periosteal\\:\\ 0\\.005354484133644309\ \(0\)\
\-\ medicine\\:\\ 0\\.005354484133644309\ \(0\)\
\-\ tissue\\:\\ 0\\.0053511788334282525\ \(0\)\
\-\ associated\\:\\ 0\\.005327510071090362\ \(0\)\
\-\ 90\\:\\ 0\\.005321039208962289\ \(0\)\
\-\ b\\:\\ 0\\.005321039208962289\ \(0\)\
\-\ 80\\:\\ 0\\.005310076457555822\ \(0\)\
\-\ the\\:\\ 0\\.00529620773633441\ \(0\)\
\-\ discussion\\:\\ 0\\.00528842016987329\ \(0\)\
\-\ 3\\:\\ 0\\.005286593201338282\ \(0\)\
\-\ light\\:\\ 0\\.0052671131924229815\ \(0\)\
\-\ \\%\\:\\ 0\\.00526636996921006\ \(0\)\
\-\ osteomyelitis\\:\\ 0\\.0052461444352812515\ \(0\)\
\-\ a\\:\\ 0\\.005239099099321021\ \(0\)\
\-\ 19\\:\\ 0\\.005205179789650392\ \(0\)\
\-\ small\\:\\ 0\\.005200991504309429\ \(0\)\
\-\ is\\:\\ 0\\.005199518426278837\ \(0\)\
\-\ mri\\:\\ 0\\.005186990369655534\ \(0\)\
\-\ sensation\\:\\ 0\\.005185164195171393\ \(0\)\
\-\ 11\\:\\ 0\\.005165447352084635\ \(0\)\
\-\ reaction\\:\\ 0\\.005126875153019559\ \(0\)\
\-\ it\\:\\ 0\\.0050748966566262\ \(0\)\
\-\ factors\\:\\ 0\\.005071049777471498\ \(0\)\
\-\ lytic\\:\\ 0\\.005052953549785683\ \(0\)\
\-\ 22\\:\\ 0\\.005035101873211412\ \(0\)\
\-\ difficulty\\:\\ 0\\.00502626569335567\ \(0\)\
\-\ worse\\:\\ 0\\.005000106344219369\ \(0\)\
\-\ marrow\\:\\ 0\\.004966014027236711\ \(0\)\
\-\ below\\:\\ 0\\.0049003605681187815\ \(0\)\
\-\ frequently\\:\\ 0\\.004892378646776691\ \(0\)\
\-\ full\\:\\ 0\\.004876558050942192\ \(0\)\
\-\ children\\:\\ 0\\.004876558050942192\ \(0\)\
\-\ femur\\:\\ 0\\.004876558050942192\ \(0\)\
\-\ 2\\:\\ 0\\.0048615706644928565\ \(0\)\
\-\ underlying\\:\\ 0\\.004837816155176643\ \(0\)\
\-\ metastases\\:\\ 0\\.004822632034402885\ \(0\)\
\-\ lumbar\\:\\ 0\\.004800178168658406\ \(0\)\
\-\ site\\:\\ 0\\.004770821316895248\ \(0\)\
\-\ ed\\:\\ 0\\.004770821316895248\ \(0\)\
\-\ features\\:\\ 0\\.00476358292090499\ \(0\)\
\-\ involved\\:\\ 0\\.0047350195602535155\ \(0\)\
\-\ mass\\:\\ 0\\.004709885100188499\ \(0\)\
\-\ tissues\\:\\ 0\\.004633092109069079\ \(0\)\
\-\ pelvic\\:\\ 0\\.004633092109069079\ \(0\)\
\-\ appear\\:\\ 0\\.004620077186423093\ \(0\)\
\-\ lesion\\:\\ 0\\.00459856070277531\ \(0\)\
\-\ 25\\:\\ 0\\.004563046576297322\ \(0\)\
\-\ range\\:\\ 0\\.004544570695221048\ \(0\)\
\-\ motion\\:\\ 0\\.004538469049439945\ \(0\)\
\-\ cells\\:\\ 0\\.004526349662021133\ \(0\)\
\-\ and\\:\\ 0\\.0045180595890517185\ \(0\)\
\-\ bony\\:\\ 0\\.00451434045237615\ \(0\)\
\-\ 15\\:\\ 0\\.004502439435279233\ \(0\)\
\-\ also\\:\\ 0\\.004450778318811496\ \(0\)\
\-\ rare\\:\\ 0\\.0043835537631087135\ \(0\)\
\-\ malignancy\\:\\ 0\\.004362073550596454\ \(0\)\
\-\ second\\:\\ 0\\.004335705330566681\ \(0\)\
\-\ skin\\:\\ 0\\.004335705330566681\ \(0\)\
\-\ active\\:\\ 0\\.004309853155937755\ \(0\)\
\-\ lungs\\:\\ 0\\.0042744895614006285\ \(0\)\
\-\ commonly\\:\\ 0\\.004259618815661349\ \(0\)\
\-\ its\\:\\ 0\\.004259618815661349\ \(0\)\
\-\ tumors\\:\\ 0\\.004240048028626818\ \(0\)\
\-\ throughout\\:\\ 0\\.004225557894715887\ \(0\)\
\-\ metastasis\\:\\ 0\\.004225557894715887\ \(0\)\
\-\ which\\:\\ 0\\.004214384642648741\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.004150852254682967\ \(0\)\
\-\ intact\\:\\ 0\\.0041463205042248565\ \(0\)\
\-\ wbc\\:\\ 0\\.004115026222689316\ \(0\)\
\-\ malignant\\:\\ 0\\.0040801462039356685\ \(0\)\
\-\ 20\\:\\ 0\\.004058804803377828\ \(0\)\
\-\ weight\\:\\ 0\\.004046163520661645\ \(0\)\
\-\ obtained\\:\\ 0\\.00401303315818209\ \(0\)\
\-\ typically\\:\\ 0\\.003984710395648576\ \(0\)\
\-\ because\\:\\ 0\\.0039491655437068\ \(0\)\
\-\ side\\:\\ 0\\.003910761561115021\ \(0\)\
\-\ presentation\\:\\ 0\\.0038882439028944285\ \(0\)\
\-\ 3\\.\\:\\ 0\\.0038624494215861657\ \(0\)\
\-\ cause\\:\\ 0\\.0038193693877833106\ \(0\)\
\-\ although\\:\\ 0\\.0038123240166137435\ \(0\)\
\-\ this\\:\\ 0\\.0038089982033585193\ \(0\)\
\-\ swelling\\:\\ 0\\.003760648433264376\ \(0\)\
\-\ by\\:\\ 0\\.0037592362040815715\ \(0\)\
\-\ back\\:\\ 0\\.00372399780098742\ \(0\)\
\-\ central\\:\\ 0\\.003714176164940501\ \(0\)\
\-\ radiation\\:\\ 0\\.0037044270139528885\ \(0\)\
\-\ disease\\:\\ 0\\.0036901916544668538\ \(0\)\
\-\ often\\:\\ 0\\.0036016823626415484\ \(0\)\
\-\ 2\\.\\:\\ 0\\.003589754480581583\ \(0\)\
\-\ between\\:\\ 0\\.0035779333371522377\ \(0\)\
\-\ adjacent\\:\\ 0\\.0035691363859105246\ \(0\)\
\-\ area\\:\\ 0\\.0035691363859105246\ \(0\)\
\-\ such\\:\\ 0\\.0035288412019033716\ \(0\)\
\-\ 1\\.\\:\\ 0\\.0035260094667075308\ \(0\)\
\-\ resection\\:\\ 0\\.003520364142034635\ \(0\)\
\-\ severe\\:\\ 0\\.0034733286658731894\ \(0\)\
\-\ usually\\:\\ 0\\.00342791050708951\ \(0\)\
\-\ as\\:\\ 0\\.0034150000155723326\ \(0\)\
\-\ no\\:\\ 0\\.003409950399090364\ \(0\)\
\-\ month\\:\\ 0\\.003386544968032509\ \(0\)\
\-\ of\\:\\ 0\\.0033858436163219886\ \(0\)\
\-\ years\\:\\ 0\\.0033147201281618\ \(0\)\
\-\ evaluation\\:\\ 0\\.0032790472864290725\ \(0\)\
\-\ loss\\:\\ 0\\.0032767030019398144\ \(0\)\
\-\ lung\\:\\ 0\\.0032696950069204043\ \(0\)\
\-\ weeks\\:\\ 0\\.0032038015282710016\ \(0\)\
\-\ edema\\:\\ 0\\.003192765507835259\ \(0\)\
\-\ chronic\\:\\ 0\\.003179642843998679\ \(0\)\
\-\ include\\:\\ 0\\.0031666492576357817\ \(0\)\
\-\ low\\:\\ 0\\.003138927414618758\ \(0\)\
\-\ an\\:\\ 0\\.0031219679373440685\ \(0\)\
\-\ history\\:\\ 0\\.0031181361630306034\ \(0\)\
\-\ trauma\\:\\ 0\\.003087197862295811\ \(0\)\
\-\ months\\:\\ 0\\.003083145699722678\ \(0\)\
\-\ cell\\:\\ 0\\.003049195127584526\ \(0\)\
\-\ up\\:\\ 0\\.0030354651929382077\ \(0\)\
\-\ therapy\\:\\ 0\\.0030180195458924873\ \(0\)\
\-\ common\\:\\ 0\\.0029541178493479488\ \(0\)\
\-\ who\\:\\ 0\\.0029431550979414824\ \(0\)\
\-\ over\\:\\ 0\\.0028740324836723417\ \(0\)\
\-\ increased\\:\\ 0\\.002761538681373389\ \(0\)\
\-\ surgery\\:\\ 0\\.002741081987265885\ \(0\)\
\-\ imaging\\:\\ 0\\.0026447474563482203\ \(0\)\
\-\ was\\:\\ 0\\.002611037046799701\ \(0\)\
\-\ posterior\\:\\ 0\\.00260190032853692\ \(0\)\
\-\ can\\:\\ 0\\.0025603994088098676\ \(0\)\
\-\ case\\:\\ 0\\.0024696227646859585\ \(0\)\
\-\ large\\:\\ 0\\.002468351957504729\ \(0\)\
\-\ but\\:\\ 0\\.0024075340832675532\ \(0\)\
\-\ surgical\\:\\ 0\\.002372816076950401\ \(0\)\
\-\ after\\:\\ 0\\.0023355365952565424\ \(0\)\
\-\ treatment\\:\\ 0\\.0022848308581253462\ \(0\)\
\-\ with\\:\\ 0\\.002163881724251594\ \(0\)\
\-\ \\.\\:\\ 0\\.00215717128200519\ \(0\)\
\-\ has\\:\\ 0\\.0021198150204680024\ \(0\)\
\-\ male\\:\\ 0\\.00204122263921727\ \(0\)\
\-\ that\\:\\ 0\\.0019497763917553808\ \(0\)\
\-\ there\\:\\ 0\\.0016799412899141197\ \(0\)\
\-\ from\\:\\ 0\\.0016729665959765024\ \(0\)\
\-\ at\\:\\ 0\\.0015294097131197265\ \(0\)\
\-\ year\\:\\ 0\\.0012630188497660697\ \(0\)\
\-\ old\\:\\ 0\\.0011557920698312479\ \(0\)\
\-\ patient\\:\\ 0\\.0011315613354245548\ \(0\)\
\-\ for\\:\\ 0\\.0009631547538212882\ \(0\)\
\-\ on\\:\\ 0\\.0009562628961234189\ \(0\)\
